UC Irvine

UC Irvine Previously Published Works

Title

IKK-dependent activation of NF- κ B contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1.

Permalink

<https://escholarship.org/uc/item/9669c8m0>

Journal

Blood, 123(15)

ISSN

1528-0020

Authors

Hsieh, Mo-Ying
Van Etten, Richard A

Publication Date

2014-04-10

Peer reviewed

Regular Article

MYELOID NEOPLASIA

IKK-dependent activation of NF- κ B contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1Mo-Ying Hsieh^{1,2} and Richard A. Van Etten^{1,3}¹Molecular Oncology Research Institute, Tufts Medical Center, Boston, MA; ²Program in Molecular and Cellular Physiology, Sackler School of Graduate Biomedical Sciences, Tufts University School of Medicine, Boston, MA; and ³Division of Hematology/Oncology, Tufts Medical Center, Boston, MA

Key Points

- Inhibitors of NF- κ B activation attenuate lymphoid and myeloid leukemogenesis by BCR-ABL1 and decrease leukemic stem cells in vivo.
- These results validate IKKs and NF- κ B signaling as pharmacological targets for therapy of CML and Ph⁺ B-ALL.

The product of the Ph chromosome, the BCR-ABL1 tyrosine kinase activates diverse signaling pathways in leukemic cells from patients with chronic myeloid leukemia (CML) and Ph⁺ B-cell acute lymphoblastic leukemia (B-ALL). Previous studies showed that nuclear factor κ B (NF- κ B) is activated in BCR-ABL1-expressing cells, but the mechanism of activation and importance of NF- κ B to the pathogenesis of BCR-ABL1-positive myeloid and lymphoid leukemias are unknown. Coexpression of BCR-ABL1 and a superrepressor mutant of inhibitory NF- κ B α (IkB α SR) blocked nuclear p65/RelA expression and inhibited the proliferation of Ba/F3 cells and primary BCR-ABL1-transformed B lymphoblasts without affecting cell survival. In retroviral mouse models of CML and B-ALL, coexpression of IkB α SR attenuated leukemogenesis, prolonged survival, and reduced myeloid leukemic stem cells. Coexpression of dominant-negative mutants of IkB kinase α (IKK α)/IKK1 or IKK β /IKK2 also inhibited lymphoid and myeloid leukemogenesis by BCR-ABL1. Blockade of NF- κ B decreased expression of the NF- κ B targets c-MYC and BCL-X and increased the sensitivity of BCR-ABL1-transformed lymphoblasts to ABL1

kinase inhibitors. These results demonstrate that NF- κ B is activated through the canonical IKK pathway and plays distinct roles in the pathogenesis of myeloid and lymphoid leukemias induced by BCR-ABL1, validating NF- κ B and IKKs as targets for therapy of Ph⁺ leukemias. (*Blood*. 2014;123(15):2401-2411)

Introduction

The BCR-ABL1 tyrosine kinase, product of the Philadelphia chromosome translocation, is the direct cause of chronic myeloid leukemia (CML) and is also implicated in ~20% of acute B-lymphoblastic leukemias (Ph⁺ B-cell acute lymphoblastic leukemia [B-ALL]). ABL1 tyrosine kinase inhibitors (TKIs) such as imatinib induce cytogenetic remissions in the majority of CML patients, but relapse occurs quickly in most patients after a TKI is withdrawn,¹ while those with advanced stages of CML or with B-ALL are less responsive to TKI therapy and frequently develop TKI resistance.² Quiescent CML stem cells, which are resistant to killing by TKIs, are proposed to be the source of disease persistence and relapse.^{3,4} Hence, there is a need to identify and validate additional pharmacological targets in Ph⁺ leukemia to overcome TKI resistance and eradicate disease, leading to permanent cure.⁵

BCR-ABL1 activates multiple signaling networks in leukemic cells, including the RAS/mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription (STAT), c-Jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK), phosphatidylinositol 3-kinase (PI3K), nuclear factor κ B (NF- κ B), and c-MYC pathways,⁶ but a major challenge has been determining which of these pathways are essential to leukemogenesis. Mouse models of BCR-ABL1-induced leukemia can be valuable in this effort, as both CML and Ph⁺ B-ALL can be reproduced faithfully in

mice by expressing BCR-ABL1 in bone marrow (BM) progenitors through retroviral transduction and transplantation.⁷ Recipients of BCR-ABL1-transduced BM develop a fatal CML-like myeloproliferative neoplasm (MPN) that originates from hematopoietic stem cells, can progress to blast crisis, and is responsive to kinase inhibitor therapy,⁸ providing a physiologically relevant model of CML in primary hematopoietic cells. To model B-ALL in mice, BM is transduced in the absence of myeloid cytokines, resulting in development of an aggressive B-lymphoblastic leukemia/lymphoma in transplant recipients.⁹ This disease originates from early lymphoid progenitors⁸ and is characterized by a block in B-cell differentiation at the pre-B stage.⁹

NF- κ B is a potential downstream target of BCR-ABL1 due to its role in regulating cell survival and proliferation. The NF- κ B transcription factor family consists of 5 members, p50/NF- κ B1, p52/NF- κ B2, RelA/p65, RelB, and c-Rel, that act as homo- or heterodimers to activate transcription of target genes.¹⁰ In quiescent or unstimulated cells, NF- κ B is retained in cytoplasm by a family of inhibitory NF- κ B (IkB) inhibitor proteins, including IkB α , IkB β , IkB ϵ , and Bcl-3. In the canonical pathway regulating innate immunity and inflammation, the stability of IkB is controlled by the IkB kinase (IKK) complex, composed of 2 catalytic subunits, IKK α (IKK1) and IKK β (IKK2), and a regulatory subunit, IKK γ (NF- κ B essential modulator

Submitted January 6, 2014; accepted January 17, 2014. Prepublished online as *Blood* First Edition paper, January 24, 2014; DOI 10.1182/blood-2014-01-547943.

The online version of this article contains a data supplement.

The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.

© 2014 by The American Society of Hematology

[NEMO]). Upon stimulation, IKK phosphorylates I κ B and causes its ubiquitination and degradation, releasing NF- κ B to enter the nucleus and activate target genes. In the noncanonical pathway, IKK α plays the major role in activation of p52-RelB dimers to regulate development of secondary lymphoid organs, as well as B-cell maturation and survival.¹¹

Previous in vitro studies have shown that NF- κ B is activated in BCR-ABL1-expressing cell lines^{12,13} and in primary blasts from patients with advanced CML¹⁴ and Ph⁺ B-ALL.¹⁵ However, whether NF- κ B plays a role in the pathogenesis of leukemias induced by BCR-ABL1 is unknown. It is also unclear whether the IKK complex is involved in activation of NF- κ B in BCR-ABL1-expressing cells, as some studies suggest that BCR-ABL1-evoked NF- κ B activation is mediated by IKK,¹⁶ while others suggest an IKK-independent mechanism.^{14,15} Here, we used the mouse retroviral model of CML and Ph⁺ B-ALL to determine the role of NF- κ B signaling in myeloid and lymphoid leukemogenesis by BCR-ABL1. Our findings validate the NF- κ B pathway and particularly IKKs as promising targets for therapy of Ph⁺ leukemia.

Materials and methods

Retroviral constructs

To coexpress BCR-ABL1 and dominant-negative inhibitors of the NF- κ B pathway, complementary DNAs (cDNAs) encoding superrepressor mutant of I κ B α (I κ B α SR)¹⁷ and kinase-inactive mutants of IKK α (IKK α KM) and IKK β (IKK β KM)¹⁸ were cloned into the pMIGR1 vector¹⁹ in place of green fluorescent protein (GFP). An I κ B α SR cDNA without the 5' and 3' untranslated regions was polymerase chain reaction (PCR) amplified from the plasmid MSCV-eGFP-SR-I κ B α (kind gift of Dr M. A. Shipp, Dana-Farber Cancer Institute, Boston, MA¹⁷), while cDNAs for FLAG-tagged IKK α -KM and IKK β -KM constructs¹⁸ were amplified by PCR from pCR-FLAG-IKK α -KM or pCR-FLAG-IKK β -KM plasmids (obtained from Addgene). Primer sequences are available upon request. The respective cDNAs were introduced into pMIGR1 3' of the internal ribosome entry site (IRES) and the BCR-ABL1 cDNA (p210 isoform) subsequently inserted 5' of the IRES.

Generation of retrovirus stocks

Replication-defective ecotropic retroviral stocks were generated by transient transfection of 293 cells using the *kat* packaging system and titered by transduction of NIH3T3 cells, as described. Transduction frequency was assessed by flow cytometric detection of GFP or, in the case of bicistronic viruses coexpressing BCR-ABL1 and I κ B α SR or IKK α /IKK β , by Southern blot analysis of proviral DNA content in genomic DNA.²⁰ Titers determined by both methods were concordant. Viral stocks were matched by comparing the proviral copy number induced by serial dilutions and selecting concentrations that yield equivalent transduction in primary BM cells (supplemental Figure 1, available on the Blood Web site).

Transformation of cytokine-dependent hematopoietic cell lines

Ba/F3 cells were transduced with BCR-ABL1 retroviruses, selected for growth in the absence of interleukin-3 (IL-3), and growth assessed within 72 hours as described previously.²¹

BM transduction, transformation, and transplantation

All mouse experiments were approved by the Institutional Animal Use and Care Committee of Tufts Medical Center. Induction of B-ALL and CML-like MPN in the retroviral BM transduction/transplantation model system has been described in detail elsewhere.²⁰ For assessment of myeloid colony formation, 1×10^4 transduced cells were plated in triplicate in cytokine-free methylcellulose (Stem Cell Technologies), and colonies were counted on day 14. Assessment of BCR-ABL1 B-lymphoid transformation by pre-B-cell

colony formation in agarose²² and stromal-dependent growth²³ was performed as described.

For limiting dilution secondary transplantation, primary mice ($n = 2-4$) with established CML-like MPN induced by BCR-ABL1/GFP, BCR-ABL1/I κ B α SR, or BCR-ABL1/IKK α KM retroviruses were sacrificed, total BM isolated and pooled, and serial dilutions injected IV into cohorts ($n = 5$ per cell dose) of lethally irradiated secondary Balb/c recipient mice. A diagnosis of MPN was established in secondary recipients by presence of circulating CD11b⁺ cells $> 10^4/\mu\text{L}$ and evidence of maturing myeloid infiltration of spleen, liver, and lungs at necropsy. Estimation of leukemia stem cell frequency and statistical analysis were performed by the extreme limiting dilution analysis method and software.²⁴

Southern blot analysis

To determine the frequency of leukemia-initiating cells, distinct proviral integration events were quantitated by Southern blot analysis of genomic DNA from leukemia tissues, as described.²¹ For leukemias induced by BCR-ABL1/I κ B α SR retrovirus or by BCR-ABL1/IKK α /IKK β KM retroviruses, genomic DNA was digested with BglII or NsiI, respectively, transferred to nylon membranes and hybridized with a radioactive probe derived from the IRES. To determine proviral copy number per cell, genomic DNA was digested with BglII, and subjected to Southern blot analysis with a radioactive probe derived from human *c-ABL1* gene, which detects a common 2.2-kb fragment from each BCR-ABL1 provirus, as described.²¹

Immunoblot analysis

Lysates were prepared from primary tumor cell suspensions from BM and spleen by direct boiling, fractionated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and immunoblotted as described previously.⁹ Antibodies against ABL1 were obtained from BD Pharmingen, antibodies against total and phospho-I κ B α were obtained from Cell Signaling, antibodies against c-Myc were from Santa Cruz Biotechnology, and antibodies against actin were from Sigma-Aldrich.

Immunofluorescence analysis of nuclear RelA

Transformed B-lymphoid cells were washed with cold phosphate-buffered saline (PBS), fixed with 2% paraformaldehyde (Electron Microscopy Sciences) on ice for 20 minutes, and permeabilized with 100% methanol (Fisher Chemical) for 20 minutes on ice. Cells were then washed and blocked with PBS containing 0.1% Triton X-100, 5% fetal bovine serum (FBS), and mouse Fc block (BD Pharmingen) on ice for 10 minutes. After blocking, cells were incubated with 1:50 anti-p65/RelA (Santa Cruz Biotechnology) antibody at room temperature for 1 hour, followed by incubation with 1:200 secondary Alexa Fluor 555-conjugated goat anti-rabbit (Invitrogen) at room temperature for 30 minutes. Cells were then washed PBS/0.05% Triton X-100/2.5% FBS, placed on coverslips by cytospin (Shandon), and imaged using a Leica TCS SP2 confocal microscope with Leica Confocal LCS software.

Cell viability assay with TKIs

Primary B-lymphoid cells were plated in triplicate in 96-well plates in RPMI 1640 medium supplemented with 20% FBS (Gibco/Life Technologies), 200 μM L-glutamine (Cellgro), 50 μM 2-mercaptoethanol (EMD), and 1 mg/mL ciprofloxacin (Sigma-Aldrich). Imatinib or dasatinib were included in the medium at increasing concentrations. At 96 hours postincubation, cell viability was determined by the MTS assay (Promega), following the manufacturer's instructions.

Results

NF- κ B contributes to BCR-ABL1-mediated lymphoid transformation in vitro

To address whether NF- κ B is involved in BCR-ABL1-induced transformation and leukemogenesis, we first used I κ B α SR to block NF- κ B

Figure 1. κ B α SR inhibits in vitro B-lymphoid transformation by BCR-ABL1. (A) Ba/F3 parental cells or cells transduced with retrovirus expressing BCR-ABL1/GFP or BCR-ABL1/ κ B α SR (4×10^4) were plated in triplicate in the absence of IL-3, and viable cells determined by trypan blue staining. The difference in cell number between BCR-ABL1/GFP-expressing and BCR-ABL1/ κ B α SR-expressing Ba/F3 at 96 hours was significant ($P < .0001$, Student t test). (B) Immunoblot of extracts from the cell lines in panel A, demonstrating expression of I κ B α SR. (C) Representative confocal photomicrographs of nuclear RelA expression in Ba/F3 parental cells unstimulated or treated with TNF α (20 ng/mL) for 15 minutes, and Ba/F3 cells expressing BCR-ABL1/GFP or BCR-ABL1/ κ B α SR. Cells were stained with antibody against RelA (red) and counterstained with Hoechst dye (blue). Scale bars = 10 μ m. (D) Quantification of nuclear RelA fluorescence intensity per cell in the populations shown in panel C by confocal immunofluorescence microscopy. Data are presented as MFI of nuclear RelA staining relative to cells expressing BCR-ABL1/GFP (error bars indicate SE). The differences between unstimulated and TNF α -stimulated parental Ba/F3 cells (*), and between BCR-ABL1/GFP- and BCR-ABL1/ κ B α SR-expressing Ba/F3 cells (**), were significant ($P = .0003$ and $P = .0074$, respectively, Student t test). (E) Transformation of primary B-lymphoid progenitors in vitro. BM was transduced with BCR-ABL1/GFP or BCR-ABL1/ κ B α SR retrovirus and plated in triplicate on stroma at decreasing numbers of cells per well, as indicated by the colored lines. Positive wells were scored vs time when the viable nonadherent cell number reached 10^5 per well. (F) Proliferation of primary B-lymphoid progenitors transformed by BCR-ABL1/GFP or BCR-ABL1/ κ B α SR. Cells (4×10^4) were seeded at day 0. Viable cells were determined by colorimetric assay for reduction of dimethylthiazol diphenyltetrazolium. The difference in viable cell number at 96 hours was significant ($P < .0001$, Student t test). (G) Representative confocal micrographs of nuclear RelA expression in B lymphoblasts expressing BCR-ABL1/GFP or BCR-ABL1/ κ B α SR. Scale bars = 10 μ m. (H) Nuclear RelA expression in the transformed cells from panel A was quantified by confocal microscopy, as described in "Materials and methods." Data are presented as mean nuclear RelA fluorescence relative to cells expressing BCR-ABL1/GFP (error bars indicate SE). The average nuclear RelA content of BCR-ABL1/ κ B α SR-transformed B-lymphoid cells was significantly decreased (* $P = .0026$, Student t test). MFI, mean of fluorescence intensity.

nuclear translocation and transactivation. I κ B α SR contains Ser to Ala mutations at positions 32 and 36, which blocks phosphorylation of I κ B α SR by its regulatory kinase(s) and prevents its subsequent degradation. Ba/F3 cells were transduced with retrovirus coexpressing BCR-ABL1 (p210 isoform) and either GFP or I κ B α SR, and the growth of cells in the absence of IL-3 was assessed shortly after transduction (Figure 1A). We observed significantly decreased growth of Ba/F3 cells coexpressing BCR-ABL1 and I κ B α SR that was due to

a primary decrease in the proliferation rate, as there was no significant difference in apoptosis between the 2 populations (data not shown). Ba/F3 cells transduced with BCR-ABL1/ κ B α SR expressed a higher mobility I κ B species that was recognized by anti-I κ B α antibody but not by antiphospho-I κ B α antibody (confirming that the mutant I κ B α SR is resistant to phosphorylation), and exhibited lower levels of endogenous I κ B, consistent with reduced NF- κ B activity (Figure 1B). Consistent with previous studies,¹⁴ there was increased

Figure 2. $\kappa B\alpha SR$ expression prolongs survival of mice with $BCR-ABL1$ -induced B-ALL. (A) Kaplan-Meier survival curve for recipients of $BCR-ABL1/GFP$ - or $BCR-ABL1/\kappa B\alpha SR$ -transduced BM. The number of individual mice in each arm is indicated; all mice developed B-ALL. Mice with B-ALL induced by the $BCR-ABL1/\kappa B\alpha SR$ retrovirus survived significantly longer than control ($P = .0096$, Mantel-Cox test). (B) Genomic DNA from pleural effusion lymphoblasts of B-ALL mice was subjected to Southern blot analysis to quantify leukemia-initiating cells, as described in "Materials and methods." The difference in number of proviral clones between leukemias induced by $BCR-ABL1/GFP$ (lanes 1-10, 8.1 ± 3.5 independent clones) or $BCR-ABL1/\kappa B\alpha SR$ (lanes 11-22, 5.8 ± 2.0 independent clones) was of borderline significance ($P = .0697$, Student t test). The 2 control DNAs (Con, lanes 23-24) were from cell lines that each contained a single $BCR-ABL1$ provirus. The same blot was reprobed with a human $ABL1$ probe to calculate the total proviral copy number per genome, as described.²¹

phospho- $\kappa B\alpha$ in cells expressing $BCR-ABL1$ alone relative to parental cells, whereas coexpression of $\kappa B\alpha SR$ with $BCR-ABL1$ reduced phospho- $\kappa B\alpha$. Expression of $BCR-ABL1$ increased nuclear RelA to a similar extent as in parental Ba/F3 cells stimulated with the NF- κB agonist tumor necrosis factor α (TNF α), while cells coexpressing $BCR-ABL1$ and $\kappa B\alpha SR$ showed significantly reduced nuclear RelA expression (Figure 1C-D).

We next asked whether NF- κB contributes to $BCR-ABL1$ -mediated transformation and proliferation of primary B-lymphoid progenitors on stroma.²³ Whereas cultures initiated with as few as 3000 progenitors transduced with $BCR-ABL1/GFP$ retrovirus reached confluence, at least 10-fold more $BCR-ABL1/\kappa B\alpha SR$ -transduced progenitors were required for the same outcome, with a delay of ~ 3 days in time to reach confluence (Figure 1E). As in Ba/F3 cells, the effect of inhibition of NF- κB on B-lymphoblast growth was primarily a decrease in cell proliferation (Figure 1F) without affecting cell survival (supplemental Figure 2). $BCR-ABL1/\kappa B\alpha SR$ -transformed primary B-lymphoid progenitors had significantly lower nuclear RelA expression than cells transformed by $BCR-ABL1/GFP$ (Figure 1G-H). These results indicate that NF- κB contributes to transformation of B-lymphoid progenitors by $BCR-ABL1$.

NF- κB is required for efficient induction of lymphoid and myeloid leukemias by $BCR-ABL1$

We next assessed whether inhibition of NF- κB through coexpression of $\kappa B\alpha SR$ would affect $BCR-ABL1$ -mediated leukemogenesis in vivo. To induce B-ALL in mice, BM from non-5-fluorouracil (5-FU)-treated donors was transduced with matched-titer retroviruses expressing $BCR-ABL1/GFP$ or $BCR-ABL1/\kappa B\alpha SR$, followed by transplantation into irradiated syngeneic mice.⁹ Recipients of BM transduced with $BCR-ABL1/GFP$ developed fatal B-ALL with a median survival of 4 weeks (Figure 2A), characterized by circulating malignant $BP1^+B220^+$ cells in peripheral blood, lymphadenopathy, moderate splenomegaly (average weight 0.3 g), and a hemorrhagic malignant pleural effusion (supplemental Figure 3). Mice transplanted with $BCR-ABL1/\kappa B\alpha SR$ -transduced marrow also developed B-ALL with similar pathological features but had a modest but significant increase in their survival (Figure 2A). Lymphoblasts from mice with B-ALL induced by $BCR-ABL1/\kappa B\alpha SR$ had decreased nuclear RelA

expression relative to leukemic cells expressing $BCR-ABL1/GFP$ (supplemental Figure 4).

To determine the effect of inhibiting NF- κB on the frequency of leukemia-initiating or leukemia stem cells in mice with $BCR-ABL1$ -induced B-ALL, we quantified the number of unique proviral clones in leukemic cells from individual recipient mice in the 2 cohorts by Southern blotting (Figure 2B). Mice with B-ALL who were recipients of $BCR-ABL1/GFP$ -transduced BM showed an oligoclonal to polyclonal pattern of leukemia-initiating cells, with an average of 8.1 ± 3.5 independent proviral clones per leukemic recipient. Leukemias that developed in recipients of $BCR-ABL1/\kappa B\alpha SR$ -transduced marrow exhibited a lower average number of proviral clones (5.8 ± 2.0), which was of borderline statistical significance ($P = .0697$, Student t test). These results demonstrate that inhibition of NF- κB attenuates B-lymphoid leukemogenesis by $BCR-ABL1$.

We next tested whether coexpression of $\kappa B\alpha SR$ affected the pathogenesis of the CML-like MPN induced by $BCR-ABL1$ in the mouse retroviral transplantation model. To induce CML-like MPN in mice, BM was harvested from donors pretreated with 5-FU and transduced with $BCR-ABL1/GFP$ or $BCR-ABL1/\kappa B\alpha SR$ retrovirus in the presence of myeloid cytokines, followed by transplantation into irradiated syngeneic recipients. All mice transplanted with $BCR-ABL1/GFP$ -transduced marrow developed CML-like MPN characterized by a greatly elevated leukocyte count in peripheral blood ($\sim 1-2 \times 10^5$ cells per μL), splenomegaly (mean spleen weight 1.2 g), lung hemorrhages, and massive expansion of $Gr-1^+Mac-1/CD11b^+$ progenitors in BM, spleen, and liver (supplemental Figure 3). Mice transplanted with $BCR-ABL1/\kappa B\alpha SR$ -transduced BM developed a similar MPN, but had significantly longer survival (Figure 3A; median survival, 25 days vs 19 days for $BCR-ABL1/GFP$ recipients; $P < .0001$, Mantel-Cox test). Southern blot analysis of leukemia-initiating cell frequency in the MPNs from the 2 cohorts (Figure 3B) showed that coexpression of $\kappa B\alpha SR$ with $BCR-ABL1$ significantly decreased the number of independent proviral clones in the malignant myeloid cells (6.8 ± 1.4 clones vs 9.9 ± 2.8 clones in $BCR-ABL1/GFP$ recipients, $P = .0096$, Student t test). These results suggest that NF- κB inhibition attenuates $BCR-ABL1$ -induced CML-like MPN in part through targeting the leukemic stem cells in this model.

Figure 3. Expression of IκBαSR attenuates CML-like MPN induced by BCR-ABL1. (A) Kaplan-Meier survival curve for CML-like MPN induced by BCR-ABL1/GFP or BCR-ABL1/IκBαSR. The number of individual mice in each arm is indicated. All mice receiving BCR-ABL1/GFP-transduced BM developed CML-like MPN; recipients of BCR-ABL1/IκBαSR-transduced BM developed CML-like MPN (■) except for 1 recipient who developed B-ALL (□), and had significantly longer survival than recipients of BCR-ABL1/GFP-transduced BM ($P < .0001$, Mantel-Cox test). (B) Analysis of leukemia-initiating cell frequency in recipients from the 2 cohorts in panel A. Leukemias induced by BCR-ABL1/GFP (lanes 1-11) had a significantly higher number of independent clones (9.9 ± 2.8) than leukemias induced by BCR-ABL1/IκBαSR (lanes 12-19; 6.8 ± 1.4 clones, $P = .0096$, Student t test). The control DNA (C, lane 20) was from a cell line that each contained a single BCR-ABL1 provirus. (C) Immunoblot of protein lysates from spleens of mice with CML-like MPN induced by BCR-ABL1/GFP (lanes 2-3) or BCR-ABL1/IκBαSR (lanes 4-5) with the indicated antibodies. Lysate from untransduced mouse BM (lane 1) served as a control. The relative expression of c-MYC was quantified and normalized to actin (bar graph).

To determine downstream signaling pathways affected by the expression of IκBαSR, protein lysates from spleens of mice with CML-like MPN induced by BCR-ABL1/GFP or BCR-ABL1/IκBαSR were subjected to immunoblot analysis. Previous reports indicated that the genes for c-Myc and the prosurvival factor Bcl-X both contain κ B binding sites and are induced by BCR-ABL1 expression.^{25,26} Consistent with these studies, expression of both c-MYC and BCL-X proteins was induced by BCR-ABL1, whereas coexpression of IκBαSR reduced the expression of c-MYC but not BCL-X (Figure 3C). As in Ba/F3 cells, myeloid leukemia cells expressing IκBαSR had reduced levels of endogenous IκB, indicative of suppression of NF- κ B signaling.

Inhibition of IKKα and IKKβ impairs BCR-ABL1-mediated B-lymphoid transformation in vitro

To investigate the mechanism of activation of NF- κ B in BCR-ABL1-expressing cells, we tested whether 2 upstream kinases that negatively regulate IκBα, IKKα/IKK1 and IKKβ/IKK2, were involved. To accomplish this, we engineered retroviruses coexpressing BCR-ABL1 and kinase-inactive mutants of IKKα (IKKαKM) or IKKβ (IKKβKM), created by substitution of alanine for lysine within the ATP binding site. The ability of the resulting IKKαKM and IKKβKM mutants to block NF- κ B activation has been demonstrated previously.¹⁸

We first tested the effect of coexpression of IKKαKM or IKKβKM on BCR-ABL1-mediated B-lymphoid transformation in the stromal growth assay.²³ Expression of either IKK mutant significantly impaired BCR-ABL1-mediated transformation, manifested both an increased time for culture outgrowth and a >30-fold increase in the number of transduced cells required to achieve maximal growth in all wells (Figure 4A). In a complementary transformation assay, colony formation in agarose,²² BM transduced with BCR-ABL1/IκBαSR retrovirus or either BCR-ABL1/IKK-KM retrovirus formed significantly fewer colonies (Figure 4B) that were much smaller in size (supplemental Figure 5) than those generated by transduction with the BCR-ABL1/GFP retrovirus. Lymphoblasts transformed by either BCR-ABL1/IKK-KM retrovirus had significantly reduced nuclear RelA expression relative to BCR-ABL1/GFP-expressing cells (Figure 4C; $P < .0001$, Student t test). Together, these results

demonstrate that blocking NF- κ B activation through inhibition of IKKs impairs BCR-ABL1-mediated B-lymphoid transformation.

Dominant-negative IKK mutants attenuate BCR-ABL1-mediated B-ALL

We next tested the effect of IKK inhibition on B-lymphoid leukemogenesis by BCR-ABL1. As before, recipients of BCR-ABL1/GFP-transduced BM succumbed to B-ALL within 4 weeks of transplantation (Figure 5A). By contrast, recipients of BM transduced with either BCR-ABL1/IKK-KM retrovirus also developed B-ALL but had significantly longer survival than BCR-ABL1/GFP recipients ($P < .0001$, Mantel-Cox test) and exhibited a milder disease phenotype, with smaller malignant pleural effusions (Figure 5B) and lymph nodes (data not shown) at the time of morbidity or death. Interestingly, inhibition of IKKα appeared to have a greater effect than IKKβ, with recipients of BCR-ABL1/IKKαKM-transduced BM surviving significantly longer than those transplanted with BCR-ABL1/IKKβKM-transduced BM (Figure 5A; $P = .0007$, Mantel-Cox test). The transformed lymphoblasts expressed the FLAG-tagged IKK-KM mutants (Figure 5C), and had decreased nuclear RelA levels compared with BCR-ABL1/GFP-transduced cells (Figure 5D-E). Coexpression of either IKK-KM mutant with BCR-ABL1 significantly reduced the number of leukemia-initiating cells in diseased recipient mice (Figure 5F), with leukemias from BCR-ABL1/IKKαKM and BCR-ABL1/IKKβKM recipients derived from 2.0 ± 1.1 and 2.7 ± 1.7 independent proviral clones, respectively, while the average clonality of BCR-ABL1/GFP-induced leukemias was 6.2 ± 1.9 ($P = .001$ and $P = .0057$, respectively, Student t test).

Dominant-negative IKK mutants impair myeloid transformation and leukemogenesis by BCR-ABL1

We further investigated whether expression of dominant-negative IKK mutants would affect primary myeloid transformation and leukemogenesis by BCR-ABL1. When expressed in mouse myeloid progenitors via retroviral transduction, BCR-ABL1 can induce myeloid colonies in the absence of exogenous cytokines.²⁷ In this assay, BM progenitors transduced by either BCR-ABL1/IKK-KM retrovirus formed fewer colonies in methylcellulose culture relative

Figure 4. Kinase-inactive IKK mutants inhibit B-lymphoid transformation by *BCR-ABL1*. BM from non-5-FU-treated Balb/c donor mice was harvested and transduced with retrovirus expressing *BCR-ABL1/GFP*, *BCR-ABL1/IKKαKM*, or *BCR-ABL1/IKKβKM*. (A) Assessment of stromal-dependent B-lymphoid transformation and growth. Nomenclature is as in Figure 1E. (B) B-lymphoid colony formation in agarose. Transduced cells (2×10^6 per plate, in duplicate) were seeded in agarose as described in "Materials and methods." Colony formation was assessed at day 14. Coexpression of IκBαSR (* $P = .0063$), IKKαKM (** $P = .0082$), and IKKβKM (** $P = .0101$) (Student t tests) significantly reduced B-lymphoid colony formation mediated by *BCR-ABL1*. (C) Quantification of nuclear RelA expression in primary B-lymphoid progenitors transformed by *BCR-ABL1/GFP*, *BCR-ABL1/IKKαKM*, or *BCR-ABL1/IKKβKM* (mean $\pm$ SE). Cells were stained with antibody against RelA and analyzed by confocal microscopy. *BCR-ABL1/IKKαKM*- and *BCR-ABL1/IKKβKM*-transformed cells showed significantly reduced nuclear RelA compared with cells transformed by *BCR-ABL1/GFP* (* $P < .0001$, Student t test).

to *BCR-ABL1/GFP* (Figure 6A), demonstrating that both IKK mutants impair cytokine-independent myelopoiesis mediated by *BCR-ABL1*.

To evaluate the role of IKK activation in CML, we induced CML-like MPN by transplanting BM from 5-FU-treated donors transduced with retrovirus expressing *BCR-ABL1/GFP*, *BCR-ABL1/IKKαKM*, or *BCR-ABL1/IKKβKM*. As before, all recipients of *BCR-ABL1/GFP*-transduced BM succumbed to CML-like MPN within 25 days of transplantation (Figure 6B). By contrast, mice receiving BM transduced with either *BCR-ABL1/IKK-KM* retrovirus survived significantly longer ($P < .0001$, Mantel-Cox test). While about half of the recipients of *BCR-ABL1/IKK-KM*-transduced BM developed MPN, the remaining recipients developed other hematopoietic malignancies such as B-ALL or histiocytic sarcoma, sometimes in combination with MPN. Mice that developed mixed CML-like MPN and B-ALL exhibited the cardinal clinicopathological features of both leukemias; such mice are frequently observed in recipients of *BCR-ABL1*-transduced BM under conditions when CML-like disease is attenuated.⁹ Immunoblot analysis confirmed the expression of the FLAG-tagged IKK-KM mutants in *BCR-ABL1*-expressing myeloid cells, and showed a consistent reduction in the level of the

antiapoptotic protein BCL-X_L in recipients of BM transduced with either *BCR-ABL1/IKK-KM* retrovirus (Figure 6C). On the other hand, reduced expression of c-MYC, which regulates proliferation in *BCR-ABL1*-transformed cells,²⁸ was more variable but was observed in some MPNs induced by *BCR-ABL1/IKKβKM*. The level of phospho-IκBα was lower in cells expressing either dominant-negative IKK mutant, consistent with decreased NF-κB activity. Together with our previous findings with IκBαSR, this suggests the canonical IKKβ-IκBα pathway may regulate both cell proliferation and survival in CML.

There was a striking reduction in the frequency of leukemia-initiating cells in the MPN induced by *BCR-ABL1/IKKαKM* (1.4 ± 0.3 clones) and *BCR-ABL1/IKKβKM* (3.3 ± 0.5 clones) retroviruses compared with the polyclonal (7.6 ± 0.6) disease induced by *BCR-ABL1/GFP* (Figure 6D; $P < .0001$ and $P = .0003$, respectively, Student t test). To determine whether inhibition of NF-κB signaling reduced the frequency of resident leukemic stem cells in mice with *BCR-ABL1*-induced MPN, we performed limiting dilution secondary transplantation of BM from primary mice with CML-like MPN induced by *BCR-ABL1/GFP*, *BCR-ABL1/IκBαSR*, and *BCR-ABL1/IKKαKM* retroviruses into cohorts of lethally irradiated secondary recipients, who were followed for development of MPN. Estimation of CML stem cell frequency from these data (Figure 6E) revealed that coexpression of either IκBαSR or IKKαKM reduced the frequency of BM cells capable of initiating MPN in secondary recipients approximately fivefold (from $\sim 1:436\,000$ for GFP to $\sim 1:2\,260\,000$ or $1:2\,160\,000$ for IκBαSR or IKKαKM, respectively; $P = .0052$ or 0.0064 , respectively, χ^2 test).

NF-κB inhibition increases the sensitivity of *BCR-ABL1*-expressing leukemic cells to TKIs

Inhibition of NF-κB signaling through coexpression of either IκBαSR or dominant-negative IKKs attenuated lymphoid and myeloid leukemogenesis by *BCR-ABL1*, validating NF-κB as a potential target for therapy in Ph⁺ leukemia. We therefore asked whether inhibition of NF-κB might enhance the sensitivity of *BCR-ABL1*-expressing leukemic cells to TKI drugs such as imatinib or dasatinib. Primary B-lymphoid progenitors transformed by *BCR-ABL1/GFP*, *BCR-ABL1/IκBαSR*, or *BCR-ABL1/IKK-KM* were cultured in vitro in the presence of increasing concentrations of TKIs. Importantly, coexpression of IκBαSR sensitized cells to imatinib, manifested by a modest but significant decrease in the IC₅₀ from 316 nM to 118 nM (Figure 7A). Similarly, coexpression of IKKαKM or IKKβKM increased the sensitivity of *BCR-ABL1*-expressing lymphoblasts to imatinib (Figure 7B), with the IC₅₀ falling from 624 nM to 171 nM and 151 nM, respectively. Coexpression of IKKαKM also sensitized the leukemic cells to the more potent second-generation TKI dasatinib, with a decrease in the IC₅₀ from 0.78 nM to 0.26 nM (Figure 7C). We did not observe any effect of inhibition of NF-κB on the sensitivity of the malignant B lymphoblasts to glucocorticoids (dexamethasone; data not shown). These results suggest that IKK inhibition in combination with TKIs may be a rational strategy for treatment of Ph⁺ leukemias.

Discussion

Despite the considerable clinical success of TKIs in the treatment of CML, we now appreciate that TKI therapy has important limitations in this disease.²⁹ While the majority of patients with chronic-phase CML achieve cytogenetic remission on imatinib or one of the second-generation TKIs, even those with undetectable *BCR-ABL1* transcripts

Figure 5. Kinase-inactive IKK mutants attenuate B-lymphoid leukemogenesis by *BCR-ABL1* in mice. (A) Kaplan-Meier survival curve for B-ALL induced in mice by *BCR-ABL1/GFP*, *BCR-ABL1/IKK α KM*, or *BCR-ABL1/IKK β KM*. The number of individual mice in each arm is indicated. All recipients developed B-ALL. Coexpression of either *IKK α KM* or *IKK β KM* significantly prolonged the survival of mice with *BCR-ABL1*-induced B-ALL ($P < .0001$, Mantel-Cox test). In addition, mice with B-ALL induced by *BCR-ABL1/IKK α KM* survived significantly longer than those induced by *BCR-ABL1/IKK β KM* ($P = .0007$, Mantel-Cox test). (B) Total cell number collected from malignant pleural effusions in leukemic mice from the cohorts in panel A. Compared with B-ALL induced by *BCR-ABL1/GFP*, recipients with B-ALL induced by *BCR-ABL1/IKK α KM* ($P = .0039$) or *BCR-ABL1/IKK β KM* ($P = .0393$, Student t test) have significantly fewer leukemic cells in malignant pleural effusions. (C) Immunoblot analysis of protein lysates from pleural effusion lymphoblasts from mice with B-ALL induced by *BCR-ABL1/GFP* (lanes 2-5), *BCR-ABL1/IKK α KM* (lanes 6-12), or *BCR-ABL1/IKK β KM* (lanes 13-17). BM from an untransplanted mouse was loaded in lane 1 as a control. Lysates were analyzed with antibodies against c-Abl, FLAG, and actin. (D) Representative confocal micrographs of nuclear RelA expression in B-lymphoid leukemic cells from recipients of BM transduced with *BCR-ABL1/GFP*, *BCR-ABL1/IKK α KM*, or *BCR-ABL1/IKK β KM*. Cells were stained with antibody against RelA (Red) and counterstained with Hoechst dye (blue) as described in "Materials and methods." Scale bars = 10 μ m. (E) Quantification of nuclear RelA expression from the data in panel D (mean $\pm$ SE). Leukemic cells expressing *BCR-ABL1/GFP* showed significantly higher nuclear RelA than cells expressing *BCR-ABL1/IKK α KM* ($*P = .0003$, Student t test) or *BCR-ABL1/IKK β KM* ($**P < .0001$, Student t test). (F) Analysis of genomic DNA from leukemic tissues of mice with B-ALL induced by *BCR-ABL1/GFP* (lanes 1-6), *BCR-ABL1/IKK α KM* (lanes 7-12), or *BCR-ABL1/IKK β KM* (lanes 13-19) by Southern blot with *IRES* probe to detect distinct proviral integration events. Two control DNAs (Con, lanes 20-21) were from cell lines that each contain a single *BCR-ABL1* provirus. B-ALLs induced by *BCR-ABL1/IKK α KM* ($P = .001$, Student t test) and *BCR-ABL1/IKK β KM* ($P = .0057$, Student t test) showed significantly decreased frequency of leukemia-initiating cells as compared with *BCR-ABL1/GFP*. Because of the lower titers consistently obtained for *BCR-ABL1* retroviruses coexpressing *IKK α / β KM* (supplemental Figure 1), we used more dilute *BCR-ABL1/GFP* retrovirus to match titers, resulting in a lower average number of proviral clones in the GFP control arm than in Figure 2B.

are at risk for rapid recurrence of leukemia when TKI therapy is discontinued.¹ Ph⁺ B-ALL is an indication for allogeneic stem cell transplantation in first remission, and despite addition of TKIs to induction chemotherapy and transplantation treatment regimens,³⁰ over half of allografted patients still relapse following the procedure.

These observations have triggered a major effort to identify critical signaling pathways in Ph⁺ leukemia whose blockade can prevent or overcome TKI resistance and perhaps lead to permanent cure of these diseases.⁵ In this regard, the NF- κ B signaling pathway is an attractive

candidate. In acute myeloid leukemia (AML), NF- κ B is activated in leukemic blasts^{31,32} and in the more primitive leukemia-initiating or leukemic stem cells,³³ but not in normal hematopoietic stem cells. Inhibition of NF- κ B signaling via several pharmacological approaches, including parthenolide derivatives,^{34,35} proteasome inhibitors,³⁶ and direct IKK inhibitors,³⁷ can induce apoptosis in AML blasts. In CML, preclinical therapeutic studies of NF- κ B inhibition have been more limited, but both proteasome³⁸⁻⁴⁰ and IKK⁴¹⁻⁴³ inhibitors induce apoptosis in CML cell lines and impair myeloid colony formation from BM of CML patients. However, it is not clear whether the cytotoxic

Figure 6. Kinase-inactive IKK mutants attenuate CML-like MPN induced by *BCR-ABL1* in mice. BM from 5-FU–treated donors was transduced with retrovirus expressing *BCR-ABL1/GFP*, *BCR-ABL1/IKK α KM*, or *BCR-ABL1/IKK β KM*, and subsequently either plated in methylcellulose culture (A) or transplanted into irradiated recipients to induce CML-like MPN (B). (A) Myeloid colony assay. Transduced BM cells (1×10^4) were seeded per plate in triplicate. Colony number was determined at day 14. The differences in colony number for *BCR-ABL1/IKK α KM* or *BCR-ABL1/IKK β KM* transduced progenitors were significant (* $P = .022$ and ** $P = .024$, Student t tests). (B) Kaplan-Meier survival curve for recipients of *BCR-ABL1*–transduced BM in the CML model. The number of mice from the different arms is indicated, with the phenotype of disease indicated by the shading of the symbol; mice with mixed hematologic disease are indicated by mixed shading. Recipients of BM transduced by *BCR-ABL1/IKK α KM* ($P < .0001$, Mantel-Cox test) or *BCR-ABL1/IKK β KM* ($P < .0001$, Mantel-Cox test) survived significantly longer than *BCR-ABL1/GFP* recipients. (C) Kinase-inactive IKK mutants inhibit BCL-X expression induced by *BCR-ABL1*–expressing myeloid progenitors. Immunoblot analysis of protein lysates from spleens of mice with CML-like MPN induced by *BCR-ABL1/GFP* (lanes 4–8), *BCR-ABL1/IKK α KM* (lanes 9–11), and *BCR-ABL1/IKK β KM* (lanes 12–14). Lysates from spleens of 3 untransplanted mice (lanes 1–3) were loaded as controls. The blot was analyzed with antibodies against *BCR-ABL1*, FLAG, I κ B α , c-MYC, and BCL-X, and actin. (D) Analysis of genomic DNA from leukemic tissues of mice with CML-like MPN induced by *BCR-ABL1/GFP* (lanes 3–10), *BCR-ABL1/IKK α KM* (lanes 11–17), or *BCR-ABL1/IKK β KM* (lanes 18–23) by Southern blot with an *IRES* probe to detect distinct proviral integration events. Two control DNAs (Con, lanes 1–2) were from cell lines that each contain a single *BCR-ABL1* provirus. CML-like MPN induced by *BCR-ABL1/IKK α KM* ($P < .0001$, Student t test) and *BCR-ABL1/IKK β KM* ($P = .0003$, t test) showed a significant reduction in leukemia-initiating cell frequency as compared with *BCR-ABL1/GFP*. Because of the lower titers consistently obtained for *BCR-ABL1* retroviruses coexpressing *IKK α /IKK β KM* (supplemental Figure 1), we used more dilute *BCR-ABL1/GFP* retrovirus to match titers, resulting in a lower average number of proviral clones in the GFP control arm than in Figure 3B. (E) Limiting dilution secondary transplantation analysis of resident BM leukemia stem cell frequency in primary mice with CML-like MPN induced by *BCR-ABL1/GFP* (black), *BCR-ABL1/IKK α KM* (red), and *BCR-ABL1/IKK β KM* (green) retroviruses. The frequency of secondary recipients who did not develop CML-like MPN (log scale) is indicated by the closed symbols; open symbols indicate all recipients developed MPN at that cell dose. Dashed lines indicate 95% confidence intervals.

effects of proteasome inhibitors such as bortezomib on CML progenitors^{39,40} is due to direct inhibition of NF- κ B or of another pathway, such as FOXO transcription factors.³⁸

Here, we have used such a genetic strategy in mouse models of CML and Ph⁺ B-ALL to demonstrate that NF- κ B contributes to myeloid and lymphoid leukemogenesis by *BCR-ABL1*. We used 2

Figure 7. Inhibition of NF- κ B sensitizes BCR-ABL1-transformed B lymphoblasts to TKIs. (A) BCR-ABL1/GFP- or BCR-ABL1/I κ B α SR-transformed primary B-lymphoid progenitors (4×10^4 cells per well) were incubated with different concentration of imatinib as indicated. Cell viability was determined by MTS assay after 96 hours' incubation. (B-C) Equal numbers of primary B-lymphoid progenitors transformed by BCR-ABL1/GFP, BCR-ABL1/IKK α KM, or BCR-ABL1/IKK β KM were incubated with different concentration of imatinib (B) or dasatinib (C) as indicated. Cell viability was determined by (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay after 96 hours' incubation. Sigmoidal curves were fitted and IC₅₀ values calculated by Prism software.

validated approaches to inhibit NF- κ B signaling in primary murine hematopoietic cells expressing BCR-ABL1. The superrepressor mutant of I κ B α , I κ B α SR, is resistant to phosphorylation by IKKs and stabilizes the I κ B α SR:NF- κ B complex in the cytoplasm.¹⁷ Dominant-negative, kinase-inactive mutants of IKK α and IKK β inhibit the serine phosphorylation and kinase activity of the IKK complex and subsequently activation of NF- κ B,¹⁸ probably through competition for upstream activators.

A previous report indicated that Ba/F3 cells expressing the p185 isoform of BCR-ABL1 increased NF- κ B-dependent transcription without an increase in nuclear NF- κ B levels,¹³ but we observed increased nuclear RelA/p65 in both Ba/F3 and primary B-lymphoid cells expressing p210 BCR-ABL1 (Figure 1C,G), while coexpression

of I κ B α SR or either IKK α KM or IKK β KM effectively inhibited NF- κ B activation. In BCR-ABL1-expressing B lymphoblasts, NF- κ B was inhibited 50% to 75% from maximal levels by I κ B α SR, whereas coexpression of either IKK α KM or IKK β KM individually with BCR-ABL1 was slightly less effective at suppressing relative levels of nuclear RelA, possibly because of compensation from the other IKK subunit. The mechanism of activation of NF- κ B by BCR-ABL1 is controversial, with studies in different cell lines suggesting either IKK-dependent^{16,42} or -independent^{12,14,15} mechanisms. Here, we observed increased serine phosphorylation of I κ B α in primary murine leukemia cells expressing BCR-ABL1 and attenuation of BCR-ABL1 leukemogenesis by both IKK α KM and IKK β KM mutants, firmly linking IKK to the activation of NF- κ B in BCR-ABL1⁺ leukemias and validating IKK as a therapeutic target in these diseases.

In physiologically accurate and quantitative mouse models of Ph⁺ leukemia, coexpression of I κ B α SR or either IKK α KM or IKK β KM with BCR-ABL1 significantly attenuated both B-ALL and CML-like MPN, evoked by BCR-ABL1 in distinct BM target cells. It is interesting that attenuation of both lymphoid and myeloid leukemogenesis by the IKK mutants (Figures 5A and 6B) was more profound than that mediated by I κ B α SR (Figures 2A and 3A) despite less effective inhibition of nuclear RelA, and that the IKK α KM mutant was more effective in this regard than IKK β KM, although IKK β is generally considered to be the principal IKK mediating activation of NF- κ B in the canonical pathway.⁴⁴ In this regard, IKK α can also directly phosphorylate RelA and mediate its nuclear translocation,⁴⁵ while substrates other than I κ B α have been implicated in pro-inflammatory, proliferative, and tumor-promoting functions of IKK.⁴⁶ The function of IKK α in the alternative pathway regulating mature B-cell development⁴⁷ might also be relevant to its role in the pathogenesis of BCR-ABL1-induced B-ALL.

The precise mechanism of the inhibition of BCR-ABL1 leukemogenesis by NF- κ B blockade will require further studies, but our data suggest differences between lymphoid and myeloid leukemias. In BCR-ABL1-expressing B lymphoblasts, the principal effect of NF- κ B inhibition was on cell proliferation rather than survival, with no significant increase in apoptosis (Figure 1F and supplemental Figure 2). By contrast, in BCR-ABL1-expressing myeloid cells, NF- κ B inhibition with dominant-negative IKKs caused decreased expression of BCL-X with variable effects on c-MYC (Figure 6C), consistent with a previous study in the Ph⁺ myeloid cell line K562.⁴⁸ Our results also implicate NF- κ B in the maintenance of BCR-ABL1 leukemia-initiating cells, rigorously defined in both primary and limiting dilution secondary transplant assays.⁴⁹ The effect of NF- κ B inhibition on these leukemic "stem" cells was more profound in the CML model than for B-ALL. Although we cannot exclude an effect of NF- κ B blockade on the initial homing and engraftment of these leukemia-initiating cells, together these results suggest that the predominant role of NF- κ B signaling in CML cells may be to inhibit apoptosis.

Based on our findings and previous studies, is NF- κ B a promising target for therapy in Ph⁺ B-ALL and CML? The answer depends in part on the magnitude of the antileukemic effect mediated by genetic inhibition of the NF- κ B pathway observed herein (where the suppression of NF- κ B activity by these dominant-negative mutants is continuous) and the extent to which this can be reproduced in patients by NF- κ B inhibitor drugs, but also on the specific pathophysiological mechanisms involved. Genetic deletion of another BCR-ABL1-induced transcription factor, STAT5, completely abolishes phenotypic CML-like MPN in this mouse model⁵⁰ but does not affect the survival of BCR-ABL1-expressing leukemic stem cells. By contrast, inhibition of NF- κ B attenuated but did not eliminate CML-like

leukemia, but did have a significant negative effect on leukemic stem cells in this disease. In BCR-ABL1-expressing B-lymphoid blasts, inhibition of NF- κ B increased their sensitivity to killing by TKIs such as imatinib. Given that relapse and long-term survival in both Ph⁺ B-ALL and CML are currently thought to be influenced predominantly by leukemic stem cells that persist in patients on TKI therapy and/or following allografting, our findings argue that NF- κ B inhibitors might facilitate eradication of these troublesome progenitors and increase the chances of permanent cure. Testing this approach in Ph⁺ leukemia patients with minimal residual disease is warranted.

Acknowledgments

This work was supported by National Institutes of Health, National Cancer Institute grant CA090576 (R.A.V.E.), and by a grant from the

Sackler Families Fund for Collaborative Cancer Biology Research (M.-Y.H. and R.A.V.E.).

Authorship

Contribution: M.-Y.H. and R.A.V.E. designed experiments and wrote the manuscript; and M.-Y.H. carried out the experiments.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

The current affiliation for R.A.V.E. is Chao Family Comprehensive Cancer Center, University of California, Irvine, Irvine, CA.

Correspondence: Richard A. Van Etten, Division of Hematology/Oncology, and Chao Family Comprehensive Cancer Center, University of California, Irvine, 839 Medical Sciences Court, Sprague Hall, Room 124, Irvine, CA 92697; e-mail: vanetten@uci.edu.

References

- Mahon FX, Réa D, Guilhot J, et al; Intergroupe Français des Leucémies Myéloïdes Chroniques. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. *Lancet Oncol*. 2010;11(11):1029-1035.
- Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. *N Engl J Med*. 2001;344(14):1038-1042.
- Graham SM, Jørgensen HG, Allan E, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to ST1571 in vitro. *Blood*. 2002;99(1):319-325.
- Corbin AS, Agarwal A, Loriaux M, Cortes J, Deininger MW, Druker BJ. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. *J Clin Invest*. 2011;121(1):396-409.
- Ahmed W, Van Etten RA. Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond. *Hematology Am Soc Hematol Educ Program*. 2013;2013:189-200.
- Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. *Blood*. 2009;113(8):1619-1630.
- Van Etten RA. Studying the pathogenesis of BCR-ABL⁺ leukemia in mice. *Oncogene*. 2002;21(56):8643-8651.
- Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph⁺ leukemia in mice. *Proc Natl Acad Sci U S A*. 2006;103(45):16870-16875.
- Roumiantsev S, de Aós IE, Varticovski L, Ilaria RL, Van Etten RA. The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. *Blood*. 2001;97(1):4-13.
- Karin M. Nuclear factor-kappaB in cancer development and progression. *Nature*. 2006;441(7092):431-436.
- Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. *Trends Immunol*. 2004;25(6):280-288.
- Hamdane M, David-Cordonnier MH, D'Halluin JC. Activation of p65 NF-kappaB protein by p210BCR-ABL in a myeloid cell line (P210BCR-ABL activates p65 NF-kappaB). *Oncogene*. 1997;15(19):2267-2275.
- Reuther JY, Reuther GW, Cortez D, Pendergast AM, Baldwin ASJ Jr. A requirement for NF-kappaB activation in Bcr-Abl-mediated transformation. *Genes Dev*. 1998;12(7):968-981.
- Kirchner D, Duyster J, Ottmann O, Schmid RM, Bergmann L, Munzert G. Mechanisms of Bcr-Abl-mediated NF-kappaB/Rel activation. *Exp Hematol*. 2003;31(6):504-511.
- Munzert G, Kirchner D, Ottmann O, Bergmann L, Schmid RM. Constitutive NF-kappaB/Rel activation in Philadelphia chromosome positive (Ph⁺) acute lymphoblastic leukemia (ALL). *Leuk Lymphoma*. 2004;45(6):1181-1184.
- Mihailovic T, Marx M, Auer A, et al. Protein kinase D2 mediates activation of nuclear factor kappaB by Bcr-Abl in Bcr-Abl⁺ human myeloid leukemia cells. *Cancer Res*. 2004;64(24):8939-8944.
- Feuerhake F, Kutok JL, Monti S, et al. NF-kappaB activity, function, and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. *Blood*. 2005;106(4):1392-1399.
- Nakano H, Shindo M, Sakon S, et al. Differential regulation of I-kappaB kinase alpha and beta by two upstream kinases, NF-kappaB-inducing kinase and mitogen-activated protein kinase/ERK kinase kinase-1. *Proc Natl Acad Sci U S A*. 1998;95(7):3537-3542.
- Pear WS, Miller JP, Xu L, et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. *Blood*. 1998;92(10):3780-3792.
- Gavrilescu LC, Van Etten RA. Applications of murine retroviral bone marrow transplantation models for the study of human myeloproliferative disorders. In: Enna SJ, Williams M, Ferkany JW, Kenakin T, Moser P, Ruggeri B, eds. *Current Protocols in Pharmacology*. Ch 14. Pagosa Springs, CO: John Wiley & Sons, Inc.; 2008.
- Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. *J Exp Med*. 1999;189(9):1399-1412.
- Warren D, Griffin DS, Mainville C, Rosenberg N. The extreme carboxyl terminus of v-Abl is required for lymphoid cell transformation by Abelson virus. *J Virol*. 2003;77(8):4617-4625.
- Smith KM, Yacobi R, Van Etten RA. Autoinhibition of Bcr-Abl through its SH3 domain. *Mol Cell*. 2003;12(1):27-37.
- Hu Y, Smyth GK. ELDA: extreme limiting dilution analysis for comparing depleted and enriched populations in stem cell and other assays. *J Immunol Methods*. 2009;347(1-2):70-78.
- Chen F, Demers LM, Vallyathan V, Lu Y, Castranova V, Shi X. Involvement of 5'-flanking kappaB-like sites within bcl-x gene in silica-induced Bcl-x expression. *J Biol Chem*. 1999;274(50):35591-35595.
- Duyao MP, Buckler AJ, Sonenshein GE. Interaction of an NF-kappa B-like factor with a site upstream of the c-myc promoter. *Proc Natl Acad Sci U S A*. 1990;87(12):4727-4731.
- Gishizky ML, Witte ON. BCR/ABL enhances growth of multipotent progenitor cells but does not block their differentiation potential in vitro. *Curr Top Microbiol Immunol*. 1992;182:65-72.
- Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. *Cell*. 1992;70(6):901-910.
- Okimoto RA, Van Etten RA. Navigating the road toward optimal initial therapy for chronic myeloid leukemia. *Curr Opin Hematol*. 2011;18(2):89-97.
- Ohno R. Changing paradigm of the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. *Curr Hematol Malig Rep*. 2010;5(4):213-221.
- Estrov Z, Manna SK, Harris D, et al. Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. *Blood*. 1999;94(8):2844-2853.
- Baumgartner B, Weber M, Quirling M, et al. Increased I-kappaB kinase activity is associated with activated NF-kappaB in acute myeloid blasts. *Leukemia*. 2002;16(10):2062-2071.
- Guzman ML, Neering SJ, Upchurch D, et al. Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. *Blood*. 2001;98(8):2301-2307.
- Guzman ML, Rossi RM, Karnischky L, et al. The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. *Blood*. 2005;105(11):4163-4169.
- Jenkins C, Hewamana S, Gilkes A, et al. Nuclear factor-kappaB as a potential therapeutic target for

- the novel cytotoxic agent LC-1 in acute myeloid leukaemia. *Br J Haematol*. 2008;143(5):661-671.
36. Guzman ML, Swiderski CF, Howard DS, et al. Preferential induction of apoptosis for primary human leukemic stem cells. *Proc Natl Acad Sci U S A*. 2002;99(25):16220-16225.
37. Frelin C, Imbert V, Griessinger E, et al. Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. *Blood*. 2005;105(2):804-811.
38. Jagani Z, Song K, Kutok JL, et al. Proteasome inhibition causes regression of leukemia and abrogates BCR-ABL-induced evasion of apoptosis in part through regulation of forkhead tumor suppressors [published correction appears in *Cancer Res*. 2009;69(17):7130]. *Cancer Res*. 2009;69(16):6546-6555.
39. Albero MP, Vaquer JM, Andreu EJ, et al. Bortezomib decreases Rb phosphorylation and induces caspase-dependent apoptosis in Imatinib-sensitive and -resistant Bcr-Abl1-expressing cells. *Oncogene*. 2010;29(22):3276-3286.
40. Heaney NB, Pellicano F, Zhang B, et al. Bortezomib induces apoptosis in primitive chronic myeloid leukemia cells including LTC-IC and NOD/SCID repopulating cells. *Blood*. 2010;115(11):2241-2250.
41. Cilloni D, Messa F, Arruga F, et al. The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance. *Leukemia*. 2006;20(1):61-67.
42. Duncan EA, Goetz CA, Stein SJ, et al. IkappaB kinase beta inhibition induces cell death in Imatinib-resistant and T315I Dasatinib-resistant BCR-ABL+ cells. *Mol Cancer Ther*. 2008;7(2):391-397.
43. Lounnas N, Frelin C, Gonthier N, et al. NF-kappaB inhibition triggers death of imatinib-sensitive and imatinib-resistant chronic myeloid leukemia cells including T315I Bcr-Abl mutants. *Int J Cancer*. 2009;125(2):308-317.
44. Li ZW, Chu W, Hu Y, et al. The IKKbeta subunit of IkappaB kinase (IKK) is essential for nuclear factor kappaB activation and prevention of apoptosis. *J Exp Med*. 1999;189(11):1839-1845.
45. Adli M, Merkhofer E, Cogswell P, Baldwin AS. IKKalpha and IKKbeta each function to regulate NF-kappaB activation in the TNF-induced/canonical pathway. *PLoS ONE*. 2010;5(2):e9428.
46. Perkins ND. Integrating cell-signalling pathways with NF-kappaB and IKK function. *Nat Rev Mol Cell Biol*. 2007;8(1):49-62.
47. Kaisho T, Takeda K, Tsujimura T, et al. IkappaB kinase alpha is essential for mature B cell development and function. *J Exp Med*. 2001;193(4):417-426.
48. Morotti A, Cilloni D, Pautasso M, et al. NF-kB inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line. *Am J Hematol*. 2006;81(12):938-945.
49. Krause DS, Fulzele K, Catic A, et al. Differential regulation of myeloid leukemias by the bone marrow microenvironment. *Nat Med*. 2013;19(11):1513-1517.
50. Walz C, Ahmed W, Lazarides K, et al. Essential role for Stat5a/b in myeloproliferative neoplasms induced by BCR-ABL1 and JAK2(V617F) in mice. *Blood*. 2012;119(15):3550-3560.

blood

2014 123: 2401-2411

doi:10.1182/blood-2014-01-547943 originally published
online January 24, 2014

IKK-dependent activation of NF- κ B contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1

Mo-Ying Hsieh and Richard A. Van Etten

Updated information and services can be found at:

<http://www.bloodjournal.org/content/123/15/2401.full.html>

Articles on similar topics can be found in the following Blood collections

[Lymphoid Neoplasia](#) (1890 articles)

[Myeloid Neoplasia](#) (1295 articles)

Information about reproducing this article in parts or in its entirety may be found online at:

http://www.bloodjournal.org/site/misc/rights.xhtml#repub_requests

Information about ordering reprints may be found online at:

<http://www.bloodjournal.org/site/misc/rights.xhtml#reprints>

Information about subscriptions and ASH membership may be found online at:

<http://www.bloodjournal.org/site/subscriptions/index.xhtml>